MARKET

SAGE

SAGE

Sage Therapeutic
NASDAQ
11.18
-0.52
-4.44%
After Hours: 11.25 +0.07 +0.63% 19:12 05/20 EDT
OPEN
11.70
PREV CLOSE
11.70
HIGH
11.75
LOW
11.00
VOLUME
3.91M
TURNOVER
0
52 WEEK HIGH
59.99
52 WEEK LOW
10.92
MARKET CAP
672.84M
P/E (TTM)
-1.3314
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at SAGE last week (0513-0517)?
Weekly Report · 1d ago
Noteworthy Thursday Option Activity: AIG, DKNG, SAGE
NASDAQ · 4d ago
Sage Therapeutics CE Says Co Open To Partnership On Huntington's Drug; Says There Is A 'Lot Of Inbound Interest'
Benzinga · 6d ago
Weekly Report: what happened at SAGE last week (0506-0510)?
Weekly Report · 05/13 10:24
Sage Therapeutics to Participate in Upcoming May Investor Conferences
Sage Therapeutics will participate in the following upcoming investor conferences in May. Sage developed the only two FDA-approved treatments indicated for postpartum depression. The Company is a biopharmaceutical company leading the way to create a world with better brain health. A live webcast of each presentation will be available on Sage's website.
Barchart · 05/07 05:30
Weekly Report: what happened at SAGE last week (0429-0503)?
Weekly Report · 05/06 10:29
Sage Therapeutics Is Maintained at Overweight by JP Morgan
Dow Jones · 05/01 15:33
Sage Therapeutics Price Target Cut to $28.00/Share From $29.00 by JP Morgan
Dow Jones · 05/01 15:33
More
About SAGE
Sage Therapeutics, Inc. is a biopharmaceutical company. The Company has developed the two FDA-approved treatments indicated for postpartum depression and is advancing a robust pipeline to target unmet needs in brain health. The Company is targeting diseases and disorders of the brain across its clinical development and earlier stage pipeline. Its product ZURZUVAE is for the treatment of postpartum depression (PPD) in adults. ZURZUVAE is a neuroactive steroid that is a positive allosteric modulator of GABA receptors, targeting both synaptic and extra synaptic GABA receptors. Its product ZULRESSO (brexanolone) CIV injection is for the treatment of PPD in individuals 15 years old and older. It is also developing a portfolio of other novel compounds that target GABA receptors, including SAGE-324, which is a novel GABAA receptor positive allosteric modulator intended for chronic oral dosing. Its second area of focus for development is novel compounds that target the NMDA receptor.

Webull offers SAGE Therapeutics Inc stock information, including NASDAQ: SAGE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SAGE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SAGE stock methods without spending real money on the virtual paper trading platform.